S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
“The Bull Market Is Officially OVER”  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
“The Bull Market Is Officially OVER”  (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The 3-Stock Retirement Blueprint (Ad)
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
“The Bull Market Is Officially OVER”  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
“The Bull Market Is Officially OVER”  (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The 3-Stock Retirement Blueprint (Ad)
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
“The Bull Market Is Officially OVER”  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
“The Bull Market Is Officially OVER”  (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The 3-Stock Retirement Blueprint (Ad)
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
S&P 500   3,957.63
DOW   33,852.53
QQQ   280.57
Three Reasons It’s Time To Get Bullish On Organigram
“The Bull Market Is Officially OVER”  (Ad)
The AP Interview: IMF head urges China to end mass lockdowns
Survivor of Virginia Walmart mass shooting files $50M suit
“The Bull Market Is Officially OVER”  (Ad)
Can I Apply for Supplemental Security Income Online?
US stocks edge lower in unsteady trading, oil prices rise
The 3-Stock Retirement Blueprint (Ad)
Why Investors Are Eating Up Restaurant Brands International
Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
NASDAQ:UTHR

United Therapeutics - UTHR Stock Forecast, Price & News

$271.03
+0.34 (+0.13%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$268.60
$271.53
50-Day Range
$203.30
$271.03
52-Week Range
$158.38
$271.92
Volume
239,592 shs
Average Volume
415,050 shs
Market Capitalization
$12.35 billion
P/E Ratio
18.44
Dividend Yield
N/A
Price Target
$282.75

United Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
4.3% Upside
$282.75 Price Target
Short Interest
Healthy
3.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.98
Upright™ Environmental Score
News Sentiment
0.32mentions of United Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$22.78 M Sold Last Quarter
Proj. Earnings Growth
12.48%
From $16.59 to $18.66 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

135th out of 1,038 stocks

Pharmaceutical Preparations Industry

46th out of 510 stocks

UTHR stock logo

About United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Stock News Headlines

United Therapeutics (NASDAQ:UTHR) Sets New 1-Year High at $271.22
UTHR United Therapeutics Corporation
ASRT or UTHR: Which Is the Better Value Stock Right Now?
United Therapeutics (UTHR) Initiates Tyvaso Study in IPF
See More Headlines
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Company Calendar

Last Earnings
11/02/2022
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
965
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$282.75
High Stock Price Forecast
$375.00
Low Stock Price Forecast
$203.00
Forecasted Upside/Downside
+4.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$475.80 million
Pretax Margin
49.05%

Debt

Sales & Book Value

Annual Sales
$1.69 billion
Cash Flow
$11.69 per share
Book Value
$100.10 per share

Miscellaneous

Free Float
39,925,000
Market Cap
$12.35 billion
Optionable
Optionable
Beta
0.59

Social Links


Key Executives

  • Dr. Martine A. Rothblatt J.D.Dr. Martine A. Rothblatt J.D. (Age 67)
    M.B.A., Ph.D., Founder, Chairman & CEO
    Comp: $3.51M
  • Mr. Michael I. Benkowitz (Age 50)
    Pres & COO
    Comp: $1.96M
  • Mr. James C. Edgemond (Age 54)
    CFO & Treasurer
    Comp: $1.42M
  • Mr. Paul A. Mahon J.D.Mr. Paul A. Mahon J.D. (Age 58)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $1.67M
  • Mr. Dewey Steadman C.F.A.
    Head of Investor Relations
  • Ms. Holly Hobson
    Associate VP of HR
  • Kevin T. Gray
    Sr. VP of Strategic Operations & Logistics
  • Mr. Patrick Poisson (Age 54)
    Exec. VP of Technical Operations
  • Mr. Gil Golden
    Sr. VP & Chief Medical Officer
  • Dr. Leigh Peterson
    VP of Product Devel.













UTHR Stock - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price forecast for 2023?

9 brokerages have issued 1-year price targets for United Therapeutics' stock. Their UTHR share price forecasts range from $203.00 to $375.00. On average, they expect the company's share price to reach $282.75 in the next year. This suggests a possible upside of 4.3% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2022?

United Therapeutics' stock was trading at $216.08 on January 1st, 2022. Since then, UTHR shares have increased by 25.4% and is now trading at $271.03.
View the best growth stocks for 2022 here
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) announced its earnings results on Wednesday, November, 3rd. The biotechnology company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.37 by $0.05. The biotechnology company had revenue of $444.70 million for the quarter, compared to analyst estimates of $421.45 million. United Therapeutics had a trailing twelve-month return on equity of 16.63% and a net margin of 38.03%. The firm's revenue for the quarter was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.84 EPS.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.68%), BlackRock Inc. (9.49%), Renaissance Technologies LLC (5.60%), State Street Corp (3.50%), Palo Alto Investors LP (1.39%) and Assenagon Asset Management S.A. (1.35%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $271.03.

How much money does United Therapeutics make?

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $12.35 billion and generates $1.69 billion in revenue each year. The biotechnology company earns $475.80 million in net income (profit) each year or $14.70 on an earnings per share basis.

How many employees does United Therapeutics have?

The company employs 965 workers across the globe.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.

This page (NASDAQ:UTHR) was last updated on 11/30/2022 by MarketBeat.com Staff